| Clinical data | |
|---|---|
| Trade names | Humalog, Liprolog, Admelog, others |
| Other names | URLi, LY900014, LY-275585, insulin lispro-aabc |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a697021 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| Drug class | Insulin (short acting) |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | Within 30 min[3] |
| Duration of action | ~5 hrs[3] |
| Chemical and physical data | |
| Formula | C257H389N65O77S6 |
| Molar mass | 5813.63 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Insulin lispro, sold under the brand name Humalog among others, is a type of insulin used to treat type 1 and type 2 diabetes.[3] Typically it is taken around the time of eating.[3] It is used by injection under the skin or within an insulin pump.[3][5] Onset of effects typically occurs within 30 minutes and lasts about 5 hours.[3] Often a longer acting insulin like NPH is also needed.[3]
Common side effects include low blood sugar.[3] Other serious side effects may include low blood potassium.[3] Use in pregnancy and breastfeeding is generally safe.[6] It works the same as human insulin by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver.[3]
Insulin lispro was first approved for use in the United States in 1996.[3][7][8] It is a manufactured form of human insulin where an amino acid has been switched.[9] In the United Kingdom it costs the NHS about £1.89 per 100 units as of 2019.[5] In the United States the wholesale cost of this amount is about US$30.00.[10] In 2017, it was the 124th most commonly prescribed medication in the United States, with more than six million prescriptions.[11][12]
References edit
- ^ a b "Insulin lispro Use During Pregnancy". Drugs.com. 7 October 2019. Archived from the original on 19 September 2020. Retrieved 23 February 2020.
- ^ "Humalog 100 units/ml, solution for injection in vial - Summary of Product Characteristics (SmPC)". (emc). 30 January 2020. Archived from the original on 23 February 2020. Retrieved 23 February 2020.
- ^ a b c d e f g h i j k l m "Insulin Lispro Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 7 August 2020. Retrieved 6 September 2020.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 698. ISBN 9780857113382.
- ^ "Insulin lispro Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 19 September 2020. Retrieved 3 March 2019.
- ^ "Humalog- insulin lispro injection, solution Humalog Kwikpen- insulin lispro injection, solution Humalog Junior Kwikpen- insulin lispro injection, solution Humalog Tempo Pen- insulin lispro injection, solution". DailyMed. 25 November 2019. Archived from the original on 24 September 2019. Retrieved 23 February 2020.
- ^ "Humalog approval" (PDF). U.S. Food and Drug Administration (FDA). 14 June 1996. Archived (PDF) from the original on 24 February 2020. Retrieved 23 February 2020.
- ^ Koivisto VA (June 1998). "The human insulin analogue insulin lispro". Annals of Medicine. 30 (3): 260–6. doi:10.3109/07853899809005853. PMID 9677011.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
- ^ "Insulin Lispro - Drug Usage Statistics". ClinCalc. Archived from the original on 12 April 2020. Retrieved 11 April 2020.